Business
Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treatment Options Worldwide
CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, July 02, 2025--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for CIPN.
About this update from Asahi Kasei Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4999,"height":683,"url":"https://media.zenfs.com/en/business-wire.com/ba8e31c3a5e04729db4c5bf374c7b7de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/joos4U6CMBy4ILD4V6Jq6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ba8e31c3a5e04729db4c5bf374c7b7de","width":960,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/00ve1aZnoCHUzCRW3AyR4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ba8e31c3a5e04729db4c5bf374c7b7de","width":1200,"height":164}},"lazy":false},{"type":"text","content":"CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, July 02, 2025--(BUSINESS WIRE)--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomodulin™ Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) related symptoms. This announcement follows encouraging data from earlier Phase I and II studies performed in Japan on the efficacy of ART-123 in relieving patient symptoms without compromising existing treatment plans.","length":577,"tagName":"p"},{"type":"text","content":"Chemotherapies such as platinum-based drugs, taxanes, and vinca alkaloids are known to induce peripheral neuropathy. This condition, known as CIPN, is characterized by tingling and pain in the hands and feet, which, when severe, can impair day-to-day activities. In some cases, reduced dosage or suspension of chemotherapy may be necessary to alleviate symptoms, leading to a clinical effect on the patient’s prognosis. There are currently no drugs showing clear, established effectiveness for the prevention or treatment of CIPN, leaving patients with limited, often undesirable options.","length":588,"tagName":"p"},{"type":"text","content":"ART-123 is a recombinant human thrombomodulin (rTM) approved in Japan in 2008. Previous Phase I and II studies suggest efficacy and patient tolerability of ART-123 for CIPN by suppressing the activation of protein C and thrombin-activable fibrinolysis inhibitor (TAFI). After consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PDM...